V
VR Management, LLC
+ HoldingABVXAPGE
+26.56%
3M Return
$113.670
+1.978 (+1.74%)Zum Schluss
Loading chart…
- High
- 115.110
- Open
- 111.000
- VWAP
- 113.00
- Vol
- 991.48K
- Mkt Cap
- —
- Low
- 110.220
- Amount
- 112.04M
- EV/EBITDA, TTM
- -2.86
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
AI analysis of Abivax SA (ABVX)
buyAbivax SA is a good buy right now due to its recent funding of $920 million, which supports the U.S. launch of its drug obefazimod, and the positive analyst ratings with targets up to $180. The current RSI of 27.033 indicates the stock is oversold, suggesting a potential rebound. However, the main risk is the negative forward P/E ratio of 0, indicating uncertainty in future earnings performance.
Bewertungskennzahlen
The current forward P/E ratio for Abivax SA (ABVX) is 0.00, compared to its 5-year average forward P/E of -9.80.
Whales holding ABVX
Event-Zeitleiste
News
9.008-04Yahoo FinanceEvexta Bio Partners with Roche for Breast Cancer Clinical Trial
8.507-30NewsfilterAbivax Announces Positive Pre-NDA Interaction with FDA for Obefazimod
- 8.507-30Newsfilter
Abivax Annual Meeting Highlights and Future Outlook
8.507-10CNBCAbivax Secures Funding for U.S. Drug Launch Amid Takeover Speculation
- 8.507-10Newsfilter
Abivax Secures Funding for U.S. Drug Launch Without Big Pharma Support
ABVX FAQ — answered by Alphio AI
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others. It operates in the Healthcare sector.
Abivax SA is a good buy right now due to its recent funding of $920 million, which supports the U.S. launch of its drug obefazimod, and the positive analyst ratings with targets up to $180. The current RSI of 27.033 indicates the stock is oversold, suggesting a potential rebound. However, the main risk is the negative forward P/E ratio of 0, indicating uncertainty in future earnings performance.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.